Daniel Asse van den Noort

Biotech Turnaround Fund BV (BTF) is an independent venture capital investment firm based in Bloemendaal, The Netherlands. They also have a presence in Geyserville, California. Founded in 2000, BTF invests in both listed and unlisted firms in the biotechnology sector. BTF specializes in late-stage biotech firms that have compounds in phase II clinical trials.

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

EW Group Ltd. is a closed-end investment fund/investment trust. The company strategy is to achieve capital growth for its shareholders through the purchase, holding and sale of both minority and majority stakes in companies. The company invests in a wide range of sectors, including financial services, support services, property and resource services. The company was founded on September 15, 2004 and is headquartered in St. Peter Port, Guernsey.

Syntarga BV engages in the discovery and development of cell-killing drugs, releasable linker technologies, and linker-drug combinations. The firm also engages in the discovery and development of proprietary antibody-drug conjugate technology and products for the treatment of cancer. The company was founded in 2002 by Vincent Franciscus M. H. de Groot and Patrick Henry Beusker and is headquartered in Nijmegen, the Netherlands.

Verdes Management Plc operates as investment company. The company was founded on May 17, 2005 and is headquartered in London, the United Kingdom.

Bluewater Holding BV operates as a holding company with interests in in the supply of services and products to the oil industry. It engages in the design, engineering, project management, supply, installation and operation of Floating Production Storage Offloading and Single Point Mooring systems. The company is headquartered in Hoofddorp, the Netherlands.